Although the heterogeneity of the tumor population was assessed only for EGFR mutations in the present study, the restoration of sensitivity to osimertinib after systemic treatment may reflect the existence of a heterogeneous tumor population that could be altered in response to different pharmacologic pressures. This evidence concerns the gene EGFR and neoplasm.